Eclat Pharmaceuticals

Eclat Pharmaceuticals was a specialty pharmaceutical company based in Chesterfield, Missouri, that focused on the development and commercialization of niche brands and generic drug products. The company gained prominence for its strategy of navigating the FDA's Unapproved Drugs Initiative, successfully transitioning legacy hospital drugs to formal New Drug Application (NDA) approvals. Its key commercial successes included Bloxiverz (neostigmine methylsulfate), Vazculep (phenylephrine), and Akovaz (ephedrine sulfate), all used primarily in anesthesia and critical care settings. In March 2012, Eclat was acquired by Flamel Technologies (now Avadel Pharmaceuticals) in a deal that provided Flamel with its first marketed products and a platform for growth in the U.S. hospital market.